Skip to headlines

BUSINESS

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

CNBC BusinessTuesday, August 4, 2026 at 5:09 PM

RedScroll Brief

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs
Image via CNBC Business

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.

RedScroll Signal

Impact
High
Category
Business
Market relevance
High
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating. Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously. Investors will watch earnings, rates, and competitive positioning connected to Pfizer and Eliquis.
Read original source → CNBC BUSINESSEdition 2026-08-04

Desk copy

RedScroll Briefing

Extractive editorial brief — not a reprint of the original

What happened

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.

Why it matters

Corporate and market moves reprice risk and reveal where power and cash are concentrating.

Background

CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.

Timeline

  1. CNBC Business published: Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

  2. Story is in today’s RedScroll edition. Follow the original source for updates.

Economic impact

Investors will watch earnings, rates, and competitive positioning connected to Pfizer and Eliquis.

Related stories

Source

CNBC Business

Original reporting by CNBC Business. RedScroll provides an extractive briefing only.